Article

The FDA-approved drug apremilast suppresses alcohol intake: clinical and pre-clinical validation

2021-05-15

Abstract excerpt

Treatment options for Alcohol Use Disorders (AUD) have minimally advanced since 2004, while the annual deaths and economic toll have become alarmingly high. Bringing potential therapeutics beyond the bench and into the clinic for AUD requires rigorous pharmacological screening across molecular, behavioral, pre-clinical, and clinical studies in neuroscience. The repurposing of FDA-approved compounds is an effective...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: af184a56-21d8-578b-b6dd-4968fceeec9a
DOI: 10.1101/2021.05.13.444033

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The FDA-approved drug apremilast suppresses alcohol intake: clinical and pre-clinical validationDOI 10.1101/2021.05.13.444033Read

Current Pharmacotherapies for Alcohol Use Disorder in Italy: From Neurobiological Targets to Clinical PracticeSemantic proximity Read

Genome-Wide Expression Profiles Drive Discovery of Novel Compounds that Reduce Binge Drinking in Mice.Semantic proximity Read

Advances in Medications and Tailoring Treatment for Alcohol Use DisorderSemantic proximity Read

Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, part 1Semantic proximity Read

Antagonism of GluK1-containing Kainate Receptors Reduces Ethanol Consumption by Modulating Ethanol Reward and WithdrawalSemantic proximity Read

Alcohol in Psoriasis-From Bench to Bedside.Semantic proximity Read

Unraveling the molecular mechanisms of alcohol dependence.Semantic proximity Read

Pharmacotherapy, Pharmacogenomics, and The Future of Alcohol Dependence Treatment, Part 2Semantic proximity Read

GSK3B inhibition partially reverses brain ethanol-induced transcriptomic changes in C57BL/6J mice: Expression network co-analysis with human genome-wide association studiesSemantic proximity Read

Glucagon-Like Peptide-1 Receptor Agonists: A New Frontier in Treating Alcohol Use DisorderSemantic proximity Read

Ivermectin Reduces Withdrawal-Induced Alcohol Intake via CeA GABAergic EnhancementSemantic proximity Read

The glucagon-like peptide-1 receptor as a potential treatment target in alcohol use disorder: evidence from human genetic association studies and a mouse model of alcohol dependence.Semantic proximity Read